Wire · operational-macro
Ascendis to pay 20% Yuviwel royalties in patent settlement with BioMarin
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
Ascendis Pharma and BioMarin Pharmaceutical settled patent disputes for the drug Yuviwel in five countries, with Ascendis agreeing to pay BioMarin royalties of 18-20% on net sales through May 2030. This deal resolves litigation and grants Ascendis a broad license to continue developing CNP-based therapies.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 31 Aug 2026 and 1 Sep 2026.
◆ ◆ The Wire takeaway
The patent settlement clears legal obstacles and unlocks licensing that lets you develop CNP-based drugs freely through 2030; this deal reshapes competition, making intellectual property a lever for long-term royalties rather than blockage.
◆ Coverage
2 sources · first reported 31 Aug 2026 · latest 1 Sep 2026
◆ Related on Wire
◆ Topics